Loading
A medication that binds potassium in the gut to lower blood potassium — allowing patients with CKD to stay on protective ACEi/ARB therapy.
Potassium binders work in the GI tract to trap potassium that would otherwise be absorbed. Older agent: sodium polystyrene sulfonate (Kayexalate). Newer agents: patiromer (Veltassa) and sodium zirconium cyclosilicate (Lokelma) — both more tolerable and predictable, and studied specifically to keep patients on RAAS blockade. They are adjuncts to, not replacements for, dietary potassium control and cause-focused care.
High potassium in the blood — a common and potentially dangerous complication of CKD, especially with ACEi/ARB therapy — causing heart rhythm disturbances at severe levels.
A progressive condition characterized by gradual loss of kidney function over months or years, classified into 5 stages based on eGFR.
Advertisement
ZuvFlo is ready to integrate with your facility to streamline operations, automate compliance, and deliver better patient care.
No credit card required • Setup in under 2 hours • Cancel anytime
Advertisement
This content is a general reference, not medical advice, a diagnosis, or a treatment plan. Do not change your diet, fluids, medicines, or dialysis plan without your nephrologist or renal dietitian. Individual recommendations depend on your labs, medications, conditions, and care plan.